Appendix Table 1

Information of individual studies comprising the risk factors and life expectancy project

Study #1Study #2Study #3Study #4Study #5Study #6
N(13, 2652)(0, 957)(4, 3645)(6, 3578)(6, 5849)(25, 20566)
Mena/Womena(13/0, 2652/0)0/957(3/1, 2212/1433)(4/2, 1952/1626)(1/5, 2707/3142)(20/5, 11747/8819)
Age (mean ± SD)a(57.5 ± 4.8, 55.1 ± 5.2)40.6 ± 9.6(52.0 ± 8.6, 42.7 ± 10.2)(54.0 ± 4.0, 42.6 ± 10.2)(61.8 ± 5.6, 46.4 ± 13.8)(57.6 ± 8.2, 48.9 ± 10.7)
Age rangea(50–65, 46–66)25–69(28–57, 20–60)(49–59, 20–60)(53–68, 20–69)(32–69, 24–69)
Nature of use for samplesOccupational-basedOccupational-basedPopulation-basedPopulation-basedPopulation-basedPopulation-based
Dates of examination at baseline1979–19801981–19821983–19851983–19841985–19871984–1987
Average follow-up (yr)9.858.078.167.197.646.06
Participants rate (%)76.575.951.550.553.062.1
Study centersb1169416
Insulin resistance syndrome (%)a,c(0.0, 2.0)(0.0, 1.0)(25.0, 2.7)(33.3, 5.5)(16.6, 3.6)(8.0, 2.9)
  • a Separated into (cases, controls) for each study. Cases are participants deceased with colon or rectal cancer and controls are all other participants.

  • b Study center, numbers of centers involved in the main study.

  • c The cutpoint for variables included in the insulin resistance syndrome are determined specifically for each study.